On Thursday, Shares of Geron Corporation (NASDAQ:GERN), surged 13.11% to $3.45.
Geron Corporation declared the publication of two papers in The New England Journal of Medicine (NEJM) in which the company’s telomerase inhibitor, imetelstat, was shown to have disease-modifying activity thought to be associated with selective inhibition of the malignant progenitor cell clones responsible for the underlying disease in two hematologic myeloid malignancies, essential thrombocythemia (ET) and myelofibrosis (MF). The papers are available online in the September 3rd issue at www.NEJM.org.
“The data in the ET and MF study publications in The New England Journal of Medicine provide compelling evidence that use of a telomerase inhibitor, such as imetelstat, may result in ground-breaking changes in how we approach the future treatment of hematologic myeloid malignancies,” said John A. Scarlett, Geron’s President and Chief Executive Officer.
Geron Corporation, a clinical stage biopharmaceutical company, focuses on the development of telomerase inhibitor, imetelstat, for treating hematologic myeloid malignancies. It has partnershipand license agreement with Janssen Biotech, Inc. to develop and commercialize imetelstat worldwide for indications in oncology, counting hematologic myeloid malignancies and other human therapeutic uses.
Shares of Pericom Semiconductor Corp. (NASDAQ:PSEM), skyrocketed 37.68% to $16.77, during its last trading session, hitting its highest level.
Diodes Incorporated (DIOD), a leading global manufacturer and supplier of high-quality application specific standard products within the broad discrete, logic and analog semiconductor markets and Pericom Semiconductor Corporation declared that Diodes Incorporated and Pericom have reached a contract and Plan of Merger that provides for the acquisition of Pericom by Diodes.
Highlights of the transaction comprise:
- Combined trailing twelve months (“TTM”) stated revenue of about $1.0 billion and gross profit of about $337 million;
- Predictable to be right away accretive to Diodes’ GAAP earnings per share;
- Strengthens Diodes’ analog product offering and adds an extensive mixed-signal connectivity portfolio;
- Provides improved platform content for focused and emerging applications;
- Balances revenue contribution across target end markets;
- Enhances market and margin expansion opportunities with greater scale and value-added solutions; and
- Predictable to result in operating and administrative efficiencies.
Pericom Semiconductor Corporation designs, manufactures, and markets high-performance digital, analog, and mixed-signal integrated circuits (ICs); and frequency control products (FCPs) used in electronic systems worldwide.
Finally, Bruker Corporation (NASDAQ:BRKR), ended its last trade with -0.55% loss, and closed at $18.
Bruker Corporation, introduced four important new preclinical imaging systems at the World Molecular Imaging Congress 2015 in Honolulu, Hawaii. The novel products launched at WMIC each deliver improved performance and convenience for routine imaging, and open new horizons for advanced translational research, while Bruker’s platform philosophy facilitates multimodal imaging projects. Researchers will gain a more complete picture and deeper insights into the causes, progression, potential diagnosis and treatment of disease, accelerating the translation of preclinical results to clinical progress.
A revolutionary and proprietary gridless PET detector architecture, which is also available for Bruker’s new PET/MRI systems, makes the Albira Si the most advanced and highest performance preclinical PET system on the market. It delivers, for the first time, sub-millimeter spatial resolution across the full radial field of view (FOV), increasing the high-resolution FOV by an order of magnitude contrast to traditional PET systems. This breakthrough capability, combined with exceptional count rate performance and outstanding PET sensitivity, makes Albira Si the preferred system for dynamic and gated PET in vivo studies.
The Albira Si offers all benefits of integration with SPECT and CT. The micro-CT provides anatomical reference images and attenuation corrections for PET and SPECT imaging. In addition, the Albira Si is compatible with Bruker’s Multimodal Animal Beds for cross-platform MRI and optical molecular imaging.
Bruker Corporation, together with its auxiliaries, designs, manufactures, sells, and services proprietary life science and materials research systems, and associated products worldwide. It operates through two segments, Bruker Scientific Instruments, and Bruker Energy & Supercon Technologies.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
